全文获取类型
收费全文 | 1830篇 |
免费 | 126篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 39篇 |
妇产科学 | 7篇 |
基础医学 | 204篇 |
口腔科学 | 38篇 |
临床医学 | 200篇 |
内科学 | 830篇 |
皮肤病学 | 33篇 |
神经病学 | 49篇 |
特种医学 | 140篇 |
外科学 | 158篇 |
综合类 | 44篇 |
预防医学 | 60篇 |
眼科学 | 35篇 |
药学 | 66篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 61篇 |
出版年
2023年 | 4篇 |
2022年 | 5篇 |
2021年 | 15篇 |
2020年 | 14篇 |
2019年 | 27篇 |
2018年 | 38篇 |
2017年 | 15篇 |
2016年 | 22篇 |
2015年 | 30篇 |
2014年 | 53篇 |
2013年 | 73篇 |
2012年 | 73篇 |
2011年 | 93篇 |
2010年 | 72篇 |
2009年 | 61篇 |
2008年 | 82篇 |
2007年 | 92篇 |
2006年 | 95篇 |
2005年 | 93篇 |
2004年 | 83篇 |
2003年 | 83篇 |
2002年 | 75篇 |
2001年 | 71篇 |
2000年 | 61篇 |
1999年 | 69篇 |
1998年 | 54篇 |
1997年 | 62篇 |
1996年 | 52篇 |
1995年 | 28篇 |
1994年 | 39篇 |
1993年 | 30篇 |
1992年 | 22篇 |
1991年 | 23篇 |
1990年 | 31篇 |
1989年 | 31篇 |
1988年 | 37篇 |
1987年 | 27篇 |
1986年 | 17篇 |
1985年 | 12篇 |
1984年 | 16篇 |
1983年 | 17篇 |
1982年 | 13篇 |
1981年 | 13篇 |
1980年 | 12篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1976年 | 7篇 |
1975年 | 3篇 |
1969年 | 4篇 |
1967年 | 3篇 |
排序方式: 共有1969条查询结果,搜索用时 0 毫秒
51.
52.
Angelos Hatzakis Jeffrey V. Lazarus Evangelos Cholongitas Ricardo Baptista‐Leite Charles Boucher Cristian‐Silviu Busoi Sylvie Deuffic‐Burban Jagpreet Chhatwal Gamal Esmat Sharon Hutchinson Minerva‐Melpomeni Malliori Mojca Maticic Antons Mozalevskis Francesco Negro George A. Papandreou George V. Papatheodoridis Markus Peck‐Radosavljevic Homie Razavi Tatjana Reic Eberhard Schatz Nurdan Tozun Zobair Younossi Michael P. Manns 《Liver international》2020,40(2):260-270
The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580 000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct‐acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro‐elimination approach in specific populations is less complex and less costly than country‐wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO. 相似文献
53.
Simon Pape Tom J. G. Gevers Jan Maarten Vrolijk Bart van Hoek Gerd Bouma Carin M. J. van Nieuwkerk Richard Taubert Elmar Jaeckel Michael P. Manns Maria Papp Nora Sipeki Felix Stickel Cumali Efe Ersan Ozaslan Tugrul Purnak Frederik Nevens Dominik J. N. Kessener Alisan Kahraman Heiner Wedemeyer Johannes Hartl Christoph Schramm Ansgar W. Lohse Michael A. Heneghan Joost P. H. Drenth 《Liver international》2020,40(9):2164-2171
54.
Jared MP Bullard Arshad N Ahsanuddin Anamarija M Perry L Robbin Lindsay Mahmood Iranpour Antonia Dibernardo Paul G Van Caeseele 《The Canadian Journal of Infectious Diseases & Medical Microbiology》2014,25(6):e87-e89
A child with a complicated medical history that included asplenia acquired an infection with Babesia microti in the summer of 2013 and had not travelled outside of Manitoba. Although the clinical findings were subtle, astute laboratory work helped to reach a preliminary identification of Babesia species, while reference laboratory testing confirmed the diagnosis. Blacklegged ticks (Ixodes scapularis) are known to transmit Borrelia burgdorferi and Anaplasma phagocytophilum in the province; however, the present case represents the first known instance of tick-borne B microti, both in Manitoba and in Canada. The expanding territory of the blacklegged tick increases the relevance of this emerging infection. Clinicians, laboratory medical practitioners and public health officials should be aware of B microti as a potential locally acquired infection in Canada. 相似文献
55.
Hepatitis E has been considered to be a travel-associated, acute, self-limiting liver disease that causes fulminant hepatic failure in specific high-risk groups only. However, hepatitis E virus (HEV) infection can also be acquired in industrialized countries-HEV genotype 3 infection is a zoonosis, with pigs and rodents serving as animal reservoirs. In recent years, cases of chronic HEV infection that were associated with progressive liver disease have been described in several cohorts of immunocompromised individuals, including recipients of organ transplants. The topic of hepatitis E is therefore re-emerging and has raised the following important questions: what is the risk for HEV infection in Western countries (eg, from eating uncooked meat)? How frequently does chronic hepatitis E develop among human immunodeficiency virus-infected patients and recipients of organ transplants? What are the treatment options? What is the current status of vaccine development? What do we know about the pathogenesis of HEV infection, and why does it have a more severe course in pregnant women? This review summarizes the current knowledge on the pathogenesis and treatment of HEV infection. 相似文献
56.
57.
Hepatitis delta is the most severe of all chronic viral infections of the liver. Its agent, the hepatitis delta virus (HDV), is unique in many aspects. Because of similar transmission pathways, triple infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and HDV occurs frequently in intravenous drug users. The addition of HDV to an HIV/HBV coinfection is associated with a particularly aggressive course of liver disease, frequently leading to cirrhosis, decompensation, and death. Thus, screening for antibodies against HDV should be mandatory in all HBsAg-positive/HIV-positive patients. There is no specific treatment for HDV. The only therapeutic options currently available are long-duration interferon regimens, which are effective in <30% of the patients. Additionally, long-term treatment with HBV polymerase inhibitors as part of antiretroviral treatment may lower HBsAg- and HDV-ribonucleic acid levels in some patients. Early initiation of anti-HIV therapy seems to be reasonable in patients with hepatitis delta - even though controlled studies are not available. 相似文献
58.
59.
Modern population based oral health management requires a complete understanding of the impact of disease in order to provide efficient and effective oral health care and guidance. Periodontitis is an important cause of tooth loss and has been shown to be associated with a number of systemic conditions. The impact of oral conditions and disorders on quality of life has been extensively studied. However, the impact of periodontitis on quality of life has received less attention. This review summarizes the literature on the impact of periodontitis on oral health‐related quality of life (OHRQoL). Relevant publications were identified after searching the MEDLINE and EMBASE electronic databases. Screening of titles and abstracts and data extraction was conducted. Only observational studies were included in this review. Most of the reviewed studies reported a negative impact of periodontitis on OHRQoL. However, the reporting standards varied across studies. Moreover, most of the studies were conducted in developed countries. 相似文献
60.
Mederacke I Yurdaydin C Großhennig A Erhardt A Cakaloglu Y Yalcin K Gurel S Zeuzem S Zachou K Chatzikyrkou C Bozkaya H Dalekos GN Manns MP Wedemeyer H;Hep-Net/International Delta Hepatitis Study Group 《Journal of viral hepatitis》2012,19(6):387-395
Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNα-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNα-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by Cockcroft-Gault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNα-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/min (MDRD), respectively, P < 0.05] while no differences were observed between patients receiving adefovir alone vs combination treatment. Twenty-four weeks after treatment GFR values did not differ between treatment arms. A decrease in GFR ≥ 20% was observed more often in patients during adefovir-containing treatment vs PegIFNα-2a alone (P < 0.05) which was confirmed by Kaplan-Meier analysis. Adefovir-containing but not PegIFNα-2a treatment was associated with a decrease in GFR values in about one-fifth of patients. Combination treatment of PegIFNα-2a+ADV in chronic hepatitis B/D co-infection did not lead to any further impairment of kidney function. 相似文献